vs
Remitly Global, Inc.（RELY）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Remitly Global, Inc.的1.7倍（$772.1M vs $442.2M），Revvity净利率更高（12.7% vs 9.3%，领先3.4%），Remitly Global, Inc.同比增速更快（25.7% vs 5.9%），Revvity自由现金流更多（$161.8M vs $143.3M），过去两年Remitly Global, Inc.的营收复合增速更高（28.2% vs 9.0%）
Remitly Global是总部位于美国西雅图的跨境汇款服务提供商，2011年由马修·奥本海默、乔希·哈格与希瓦斯·古拉蒂共同创立，主要为用户提供覆盖全球170多个国家和地区的国际汇款服务，2021年9月在纳斯达克交易所上市。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
RELY vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.7倍
$442.2M
营收增速更快
RELY
高出19.8%
5.9%
净利率更高
RVTY
高出3.4%
9.3%
自由现金流更多
RVTY
多$18.5M
$143.3M
两年增速更快
RELY
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $442.2M | $772.1M |
| 净利润 | $41.2M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 8.8% | 14.5% |
| 净利率 | 9.3% | 12.7% |
| 营收同比 | 25.7% | 5.9% |
| 净利润同比 | 820.1% | 3.9% |
| 每股收益（稀释后） | $0.19 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RELYRVTY
| Q4 25 | $442.2M | $772.1M | ||
| Q3 25 | $419.5M | $698.9M | ||
| Q2 25 | $411.9M | $720.3M | ||
| Q1 25 | $361.6M | $664.8M | ||
| Q4 24 | $351.9M | $729.4M | ||
| Q3 24 | $336.5M | $684.0M | ||
| Q2 24 | $306.4M | $691.7M | ||
| Q1 24 | $269.1M | $649.9M |
净利润RELYRVTY
| Q4 25 | $41.2M | $98.4M | ||
| Q3 25 | $8.8M | $46.7M | ||
| Q2 25 | $6.5M | $53.9M | ||
| Q1 25 | $11.4M | $42.2M | ||
| Q4 24 | $-5.7M | $94.6M | ||
| Q3 24 | $1.9M | $94.4M | ||
| Q2 24 | $-12.1M | $55.4M | ||
| Q1 24 | $-21.1M | $26.0M |
毛利率RELYRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率RELYRVTY
| Q4 25 | 8.8% | 14.5% | ||
| Q3 25 | 2.8% | 11.7% | ||
| Q2 25 | 3.6% | 12.6% | ||
| Q1 25 | 3.4% | 10.9% | ||
| Q4 24 | -1.1% | 16.3% | ||
| Q3 24 | 0.1% | 14.3% | ||
| Q2 24 | -5.1% | 12.4% | ||
| Q1 24 | -7.4% | 6.8% |
净利率RELYRVTY
| Q4 25 | 9.3% | 12.7% | ||
| Q3 25 | 2.1% | 6.7% | ||
| Q2 25 | 1.6% | 7.5% | ||
| Q1 25 | 3.1% | 6.4% | ||
| Q4 24 | -1.6% | 13.0% | ||
| Q3 24 | 0.6% | 13.8% | ||
| Q2 24 | -3.9% | 8.0% | ||
| Q1 24 | -7.8% | 4.0% |
每股收益（稀释后）RELYRVTY
| Q4 25 | $0.19 | $0.86 | ||
| Q3 25 | $0.04 | $0.40 | ||
| Q2 25 | $0.03 | $0.46 | ||
| Q1 25 | $0.05 | $0.35 | ||
| Q4 24 | $-0.03 | $0.77 | ||
| Q3 24 | $0.01 | $0.77 | ||
| Q2 24 | $-0.06 | $0.45 | ||
| Q1 24 | $-0.11 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $542.4M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $868.8M | $7.3B |
| 总资产 | $1.5B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RELYRVTY
| Q4 25 | $542.4M | $919.9M | ||
| Q3 25 | $476.9M | $931.4M | ||
| Q2 25 | $515.9M | $991.8M | ||
| Q1 25 | $493.9M | $1.1B | ||
| Q4 24 | $368.1M | $1.2B | ||
| Q3 24 | $324.4M | $1.2B | ||
| Q2 24 | $185.2M | $2.0B | ||
| Q1 24 | $286.0M | $1.7B |
股东权益RELYRVTY
| Q4 25 | $868.8M | $7.3B | ||
| Q3 25 | $797.2M | $7.4B | ||
| Q2 25 | $764.9M | $7.6B | ||
| Q1 25 | $723.5M | $7.6B | ||
| Q4 24 | $665.5M | $7.7B | ||
| Q3 24 | $630.8M | $7.9B | ||
| Q2 24 | $578.9M | $7.9B | ||
| Q1 24 | $549.4M | $7.8B |
总资产RELYRVTY
| Q4 25 | $1.5B | $12.2B | ||
| Q3 25 | $1.2B | $12.1B | ||
| Q2 25 | $1.2B | $12.4B | ||
| Q1 25 | $1.1B | $12.4B | ||
| Q4 24 | $1.0B | $12.4B | ||
| Q3 24 | $970.4M | $12.8B | ||
| Q2 24 | $950.2M | $13.4B | ||
| Q1 24 | $1.1B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $149.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $143.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 32.4% | 21.0% |
| 资本支出强度资本支出/营收 | 1.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.63× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $288.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流RELYRVTY
| Q4 25 | $149.6M | $182.0M | ||
| Q3 25 | $1.4M | $138.5M | ||
| Q2 25 | $41.2M | $134.3M | ||
| Q1 25 | $132.9M | $128.2M | ||
| Q4 24 | $-27.3M | $174.2M | ||
| Q3 24 | $146.8M | $147.9M | ||
| Q2 24 | $48.9M | $158.6M | ||
| Q1 24 | $-56.8M | $147.6M |
自由现金流RELYRVTY
| Q4 25 | $143.3M | $161.8M | ||
| Q3 25 | $-2.1M | $120.0M | ||
| Q2 25 | $28.6M | $115.5M | ||
| Q1 25 | $118.9M | $112.2M | ||
| Q4 24 | $-30.1M | $149.8M | ||
| Q3 24 | $145.6M | $125.6M | ||
| Q2 24 | $47.8M | $136.6M | ||
| Q1 24 | $-57.8M | $129.7M |
自由现金流率RELYRVTY
| Q4 25 | 32.4% | 21.0% | ||
| Q3 25 | -0.5% | 17.2% | ||
| Q2 25 | 6.9% | 16.0% | ||
| Q1 25 | 32.9% | 16.9% | ||
| Q4 24 | -8.5% | 20.5% | ||
| Q3 24 | 43.3% | 18.4% | ||
| Q2 24 | 15.6% | 19.7% | ||
| Q1 24 | -21.5% | 20.0% |
资本支出强度RELYRVTY
| Q4 25 | 1.4% | 2.6% | ||
| Q3 25 | 0.8% | 2.6% | ||
| Q2 25 | 3.1% | 2.6% | ||
| Q1 25 | 3.9% | 2.4% | ||
| Q4 24 | 0.8% | 3.4% | ||
| Q3 24 | 0.3% | 3.3% | ||
| Q2 24 | 0.4% | 3.2% | ||
| Q1 24 | 0.4% | 2.7% |
现金转化率RELYRVTY
| Q4 25 | 3.63× | 1.85× | ||
| Q3 25 | 0.16× | 2.97× | ||
| Q2 25 | 6.30× | 2.49× | ||
| Q1 25 | 11.71× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 76.56× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RELY
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
